BioNTech has a broad and diversified cancer drug pipeline extending well beyond mRNA based approaches. Sam Fazeli, Senior Health Care Analyst, speaks to Ryan Richardson, Chief Strategy Officer, who explains the company’s approach to drug development, hopes for drug launches and what sets it apart from rivals.

Butterfly Leads the Drive on Semiconductor to Make the Most Out of Ultrasound
43:42

Citizen Health’s Plan to Put an AI Advocate in Every Patient’s Pocket
50:47

Distalmotion’s Approach to Spread Surgical Robots to More
36:38